GSK 1070806

Drug Profile

GSK 1070806

Alternative Names: 1070806; GSK-1070806

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 18 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Delayed graft function
  • Discontinued Inflammatory bowel diseases; Metabolic disorders; Type 2 diabetes mellitus

Most Recent Events

  • 01 Aug 2016 Phase-II clinical trials in Delayed graft function (Prevention) in United Kingdom (IV)
  • 24 Mar 2016 GlaxoSmithKline plans a phase II trial for Delayed graft function (Prevention, Combination therapy) in USA and United Kingdom (IV) (NCT02723786)
  • 01 Jan 2014 GlaxoSmithKline completes a phase II trial in Type-2 diabetes mellitus in United Kingdom and Spain (NCT01648153)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top